Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of AZD2693 in NASH Patients with PNPLA3 Risk Alleles
NCT04483947Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Primary completion
- Dec 2023
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AZD2693 in Nonalcoholic steatohepatitis (NASH) (4 cohorts), sponsored by AstraZeneca. Primary endpoint: Number of participants with adverse events at 32 weeks. Started Nov 2020; status: completed.
02
Drugs
AZD2693
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04483947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04483947.